Drug Trial Radar · NCT07095868
Evaluate the Safety, Tolerability, and Preliminary Efficacy of EVM14 Alone and in Combination in Patients With Selected Solid Tumors
Last checked: Nov 19, 2026Latest source record: Aug 4, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
94
Planned (sponsor's estimate)
Start
Nov 17, 2025
Primary completion
Nov 2029
Study completion Nov 2031
Sponsor
- Lead sponsor
- Everest Medicines (Beijing) Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Jul 31, 2025
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Brief Summary: The purpose of this clinical trial is to evaluate the safety, tolerability, preliminary efficacy, and immunogenicity of EVM14 administered intramuscularly (IM) alone and in combination with pembrolizumab in patients with selected solid tumors.
Conditions
- Selected Types of Solid Tumor
Interventions
EVM14Biological
Cancer Vaccine
PembrolizumabCombination product
Anti-PD1 antibody
Primary outcomes
What the sponsor says the trial is designed to measure.
- Phase I and Phase IIa: Incidence and severity of adverse eventsTime frame: From the the start of the first dose of study treatment to 90 days after the last study treatment or new anti-cancer treatments started, whichever occurs earlier.
- Phase I: Incidence of dose-limiting toxicities (DLT)Time frame: Mono cohort: 28-day period from the first EVM14 monotherapy dose. Combo cohort: Days 1 to 21: 21-day period from the first dose of EVM14 in combination with pembrolizumab.
- Phase IIa tumor type 1: Progression-free survival (PFS)Time frame: From the baseline to disease progression confirmed by radiological examination, the start of a new anti-cancer treatment, withdrawal of informed consent, lost to follow-up, death, or end of study, whichever occurs first. (Up to 3 years)
Locations
7 sites in 2 countries. Site status is shown where the registry gives one.
Memorial Sloan Kettering Cancer Center
New York, New York · Recruiting
MD Anderson Cancer Center
Houston, Texas · Recruiting
NEXT Oncology
Fairfax, Virginia · Recruiting
Hunan Cancer Hospital
Changsha, Hunan, China · Recruiting
Nanjing Drum Tower Hospital
Nanjing, Jiangsu, China · Recruiting
The First Affiliated Hospital With Nanjing Medical University
Nanjing, Jiangsu, China · Recruiting
Shanghai Pulmonary Hospital
Shanghai, Shanghai Municipality, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.